IDEXX Laboratories, Inc. (IDXX)
IDEXX Laboratories, Inc. (IDXX) Q3 2025 Earnings Call Transcript
IDEXX Laboratories, Inc. ( IDXX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jay Mazelsky - President, CEO & Director Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Michael Ryskin - BofA Securities, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Keith Devas - Jefferies LLC, Research Division Presentation Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2025 Earnings Conference Call.
Idexx Stock Pops on Earnings. Pet Health Is Booming.
Vet visits are down, but growing revenue per visit is more than making up for it, the company says.
Countdown to Idexx (IDXX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How IDEXX Laboratories is Placed Ahead of Q3 Earnings
IDXX heads into Q3 earnings with steady estimates and strong momentum across its diagnostics and pet healthcare segments.
Why Idexx (IDXX) is Poised to Beat Earnings Estimates Again
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IDEXX Laboratories Stock Rallies 52.9% YTD: What's Behind the Drive?
IDXX soars 52.9% YTD, fueled by strong CAG Diagnostics growth, global expansion and rising demand for software solutions.
Why Is Idexx (IDXX) Down 0.4% Since Last Earnings Report?
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Should You Add IDEXX Stock to Your Portfolio Right Now?
IDXX gains from strong CAG Diagnostics growth and rising cloud software demand, but debt levels remain a concern for investors.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
IDEXX Gains 56.2% in a Year: What's Driving the Rally?
IDXX shares surge 56.2% in a year, fueled by strong diagnostics growth, cloud software gains and an upbeat 2025 outlook.
